Aeras, Crucell and South African Tuberculosis Vaccine Initiative Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in So...(portant partners andlicensees include DS...),Health

Date:4/9/2008

portant partners and licensees include DSM Biologics, sanofi aventis, GSK and Merck & Co. Crucell is headquartered in Leiden (the Netherlands), with subsidiaries in Switzerland, Spain, Italy, Sweden, Korea and the US. The Company employs over a 1000 people. For more information, please visit http://www.crucell.com.

About SATVI

The South African Tuberculosis Vaccine Initiative is located in the Institute of Infectious Disease and Molecular Medicine at the University of Cape Town (UCT). Since 1999, with funding largely from the Aeras Global TB Vaccine Foundation, SATVI has developed the capacity to conduct registration standard vaccine trials at a site in Worcester, some 110km outside Cape Town, where rates of tuberculosis are amongst the highest in the world. SATVI has a state of the art immunology laboratory located at UCT, where the complex assays needed for TB vaccine studies can be performed. In the last 6 years SATVI has conducted a number of very large field trials and epidemiological cohort studies of the type which will be necessary to test the efficacy of new tuberculosis vaccines, involving thousands or tens of thousands of participants, as well as a number of smaller phase one and two trials of new TB vaccines. In addition, SATVI conducts cutting edge basic science research aimed at better understanding the human immune response to tuberculosis and to tuberculosis vaccines. For more information, please visit http://www.satvi.uct.ac.za.

Forward-looking statements

This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and
'/>"/>

SOURCE Aeras Global TB Vaccine Foundation Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. Trana Discovery and Southern Research Institute Announce the First RNA-RNA High Throughput Drug Screening Assay Platform for HIV Antivirals
2. Artists for a New South Africa Will be Shaking The Blues at Gala Benefit November 15, With Performances by Erykah Badu, Nikka Costa, Keb Mo, Taj Mahal Trio, The Roots, and Guest Stars at The Wiltern in Los Angeles
3. Grammy Winner Marc Cohn to Perform for African AIDS Organization at Carolina HopeFest
4. US FDA Grants Orphan Drug Status to Immtechs Pafuramidine for Treatment of African Sleeping Sickness
5. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
6. Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
7. UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
8. Immtech Receives $5.1 Million to Further African Sleeping Sickness Clinical Trials
9. Tampax and Always Launch Protecting Futures Program Dedicated to Helping African Girls Stay in School
10. New Report Offers Hope for Closing Health Gap for African Americans, With Nearly 700 Medicines in Pipeline
11. Study Shows: New Blood Test Proven Six Times More Effective For Tuberculosis Control